| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 137 | 155 | 159 | 180 | 166 | 179 | 185 | 178 | 175 | 203 | 209 | 221 | 223 | 237 | 238 | 266 | 254 | 284 | 300 | 316 | 335 | 352 | 357 | 393 | 402 | 447 | 448 |
| Expenses | 103 | 116 | 125 | 139 | 125 | 132 | 135 | 131 | 125 | 143 | 146 | 159 | 157 | 173 | 179 | 202 | 202 | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 |
| EBITDA | 35 | 39 | 35 | 41 | 41 | 47 | 50 | 47 | 50 | 60 | 63 | 63 | 66 | 64 | 59 | 64 | 51 | 74 | 86 | 92 | 101 | 99 | 108 | 112 | 121 | 142 | 138 |
| Operating Profit % | 23 % | 23 % | 20 % | 20 % | 23 % | 24 % | 25 % | 23 % | 27 % | 28 % | 28 % | 25 % | 26 % | 23 % | 22 % | 22 % | 19 % | 24 % | 25 % | 27 % | 27 % | 25 % | 27 % | 26 % | 27 % | 27 % | 27 % |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 10 | 11 | 10 | 11 | 11 | 13 | 13 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 22 |
| Interest | 4 | 7 | -1 | 2 | 3 | 2 | 5 | 8 | 3 | 3 | 5 | -2 | 3 | 0 | -1 | 2 | 1 | 0 | 5 | 2 | 3 | 2 | 4 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 22 | 23 | 26 | 30 | 28 | 36 | 34 | 29 | 36 | 46 | 46 | 52 | 50 | 50 | 46 | 49 | 36 | 59 | 67 | 75 | 83 | 81 | 88 | 93 | 99 | 118 | 113 |
| Tax | 9 | 9 | 10 | 8 | 8 | 7 | 9 | 6 | 10 | 11 | 11 | 13 | 13 | 12 | 11 | 13 | 9 | 16 | 17 | 16 | 20 | 19 | 23 | 24 | 24 | 31 | 28 |
| Net Profit | 13 | 15 | 16 | 22 | 20 | 28 | 25 | 23 | 27 | 35 | 35 | 39 | 38 | 38 | 35 | 36 | 27 | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 |
| EPS in ₹ | 1.50 | 1.65 | 1.82 | 2.44 | 2.24 | 3.22 | 2.83 | 2.57 | 3.03 | 3.97 | 4.00 | 4.26 | 3.92 | 3.99 | 3.60 | 3.77 | 2.81 | 4.53 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 9.01 | 8.48 |
Poly Medicure
2,153.95
-47.95
(-2.18%)
There are new updates from the company19 hours ago
View
Market Cap
21,825.05 Cr
EPS
26.92
PE Ratio
70.99
Dividend Yield
0.13 %
Industry
Healthcare52 Week High
3,357.80
52 Week low
1,373.00
PB Ratio
8.63
Debt to Equity
0.12
Sector
Medical Equipment
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Company News
View All News
Poly Medicure: Secures MDR Certification for 54 Products in Europe17 hours ago
Poly Medicure Ltd has received Medical Device Regulation (MDR) certification for 54 of its products in Europe, covering multiple medical specialties. This certification ensures compliance with EU safety and quality standards, potentially strengthening the company's position in the European market, which currently contributes to half of its export revenue.
Poly Medicure Receives MDR Certification for 54 Products19 hours ago
Poly Medicure has announced that it has received Medical Device Regulation (MDR) certification for 54 of its products. This certification is a significant achievement for the company, as it allows these products to be sold in the European Union market, ensuring they meet the latest safety and quality standards.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 2,153.95 | 21,825.05 | 70.99 | 1,434.50 | 24.59 | 258 | 31.08 | 46.21 | |
| 302.55 | 1,609.76 | 54.79 | 307.90 | -0.45 | 43 | -46.46 | 40.50 | |
| 407.00 | 488.52 | 28.37 | 59.30 | 30.58 | 16 | 25.00 | 36.03 | |
| 234.00 | 234.00 | - | 102.40 | -13.51 | -2 | -1,500.00 | 31.68 | |
| 221.05 | 118.30 | 74.43 | 17.80 | 136.23 | 2 | -98.33 | 32.43 | |
| 95.25 | 99.40 | 10.15 | 109.90 | -1.43 | 10 | - | 29.31 | |
| 125.00 | 41.30 | 82.78 | 14.00 | 27.27 | 1 | - | 84.07 | |
| 45.50 | 39.40 | 20.59 | 32.30 | 14.13 | 3 | 0.50 | 35.44 | |
| 75.00 | 37.80 | - | 89.80 | 17.54 | -3 | -35.71 | 38.26 | |
| 92.10 | 33.60 | 49.19 | 51.30 | -2.84 | 1 | -400.00 | 36.55 |
Growth Rate
Revenue Growth
24.59 %
Net Income Growth
44.06 %
Cash Flow Change
39.27 %
ROE
21.68 %
ROCE
22.93 %
EBITDA Margin (Avg.)
11.00 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 |
| Fixed Assets | 166 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 |
| Current Assets | 160 | 171 | 205 | 255 | 302 | 318 | 704 | 783 | 807 | 842 |
| Capital Work in Progress | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 |
| Investments | 0 | 0 | 3 | 17 | 8 | 25 | 354 | 346 | 132 | 167 |
| Other Assets | 189 | 191 | 227 | 264 | 321 | 354 | 422 | 499 | 732 | 749 |
| Total Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 |
| Current Liabilities | 113 | 109 | 114 | 123 | 154 | 193 | 171 | 227 | 293 | 351 |
| Non Current Liabilities | 55 | 50 | 72 | 104 | 119 | 139 | 87 | 63 | 42 | 37 |
| Total Equity | 196 | 229 | 272 | 338 | 381 | 435 | 966 | 1,088 | 1,242 | 1,470 |
| Reserve & Surplus | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 |
| Share Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 |
| Investing Activities | -59 | -31 | -56 | -88 | -101 | -107 | -436 | -85 | -179 | -241 |
| Operating Activities | 63 | 63 | 56 | 75 | 107 | 128 | 119 | 124 | 191 | 266 |
| Financing Activities | -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 |
Share Holding
| % Holding | Feb 2021 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Aug 2024 | Sept 2024 | Dec 2024 |
| Promoter | 44.88 % | 44.88 % | 44.77 % | 44.77 % | 44.76 % | 44.66 % | 53.34 % | 53.33 % | 53.33 % | 53.31 % | 53.31 % | 53.16 % | 53.16 % | 53.15 % | 66.03 % | 62.56 % | 62.56 % | 62.44 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.49 % | 0.00 % | 12.38 % | 9.91 % | 11.10 % | 11.87 % | 12.33 % |
| DIIs | 1.83 % | 1.92 % | 2.68 % | 2.73 % | 2.86 % | 3.18 % | 3.10 % | 3.20 % | 3.38 % | 3.68 % | 4.25 % | 5.15 % | 5.28 % | 7.22 % | 9.35 % | 12.48 % | 12.33 % | 11.66 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 15.11 % | 14.24 % | 13.69 % | 13.24 % | 12.32 % | 11.93 % | 11.20 % | 11.18 % | 11.12 % | 11.10 % | 11.35 % | 11.38 % | 11.34 % | 11.37 % | 10.70 % | 10.14 % | 10.55 % |
| Others | 37.06 % | 38.10 % | 38.30 % | 38.81 % | 39.14 % | 39.84 % | 31.63 % | 32.27 % | 32.11 % | 31.90 % | 31.34 % | 15.85 % | 30.17 % | 15.92 % | 3.36 % | 3.16 % | 3.10 % | 3.03 % |
| No of Share Holders | 0 | 19,187 | 21,531 | 35,922 | 33,678 | 35,166 | 33,831 | 33,296 | 34,239 | 35,393 | 36,141 | 34,649 | 36,053 | 36,712 | 36,852 | 40,516 | 38,352 | 60,686 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2.5 | 2 | 2 | 2 | 2.5 | 2.5 | 3 | 3 | 0.00 |
| Dividend Yield (%) | 0.00 | 1 | 0.91 | 0.86 | 0.24 | 0.26 | 0.27 | 0.19 | 0.14 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Intimation Of Receiving The Medical Device Regulation (MDR) Certification In Europe For 54 Products
Statement Of Deviation(S) Or Variation(S) For The Quarter Ended 31St December 2024.
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Acquisition
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Investor Presentation
Unaudited Financial Results (Standalone & Consolidated) For The Third Quarter And Nine Months Ended On 31St December 2024
Board Meeting Outcome for Outcome Of The Board Meeting Held On Today I.E. 03Rd February 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On 03Rd February 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Announcement under Regulation 30 (LODR)-Joint Venture
Closure of Trading Window
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Statement Of Deviation(S) Or Variation(S), If Any, Of Utilization Of Proceeds Received From Qualified Institutions Placement (QIP) Under Regulation 32 Of SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015.
Monitoring Agency Report For The Quarter Ended 30Th September, 2024 - QIP Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Change in Management
Financial Results For The Quarter And Half Year Ended On 30Th September, 2024.
Board Meeting Outcome for Outcome Of The Board Meeting Of The Company In Compliance Of Regulation 30 And 33 Of SEBI (LODR) Regulations, 2015
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Board Meeting Intimation Scheduled To Be Held On 28Th October, 2024.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Announcement under Regulation 30 (LODR)-Change in Directorate
Shareholder Meeting / Postal Ballot-Outcome of AGM
Shareholder Meeting / Postal Ballot-Outcome of AGM
Announcement under Regulation 30 (LODR)-Newspaper Publication
Business Responsibility and Sustainability Reporting (BRSR)
Intimation Of Book Closure For The Payment Of Dividend For The Financial Year 2023-24
Fixed Record Date For Determining Entitlement Of Members Eligible For Dividend
Reg. 34 (1) Annual Report.
Notice Of The 29Th Annual General Meeting Along With The Annual Report For The Financial Year 2023-24
Announcement under Regulation 30 (LODR)-Meeting Updates
Announcement under Regulation 30 (LODR)-Meeting Updates
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Meeting Updates
Otcome Of The Meeting Of QIP Committee - Company Updates
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Investor Presentation
Company Filings to Exchanges
Technical Indicators
RSI(14)
Neutral 46.21
ATR(14)
Volatile 119.36
STOCH(9,6)
Neutral 77.57
STOCH RSI(14)
Overbought 82.45
MACD(12,26)
Bullish 26.67
ADX(14)
Weak Trend 22.18
UO(9)
Bearish 64.92
ROC(12)
Downtrend And Accelerating -0.10
WillR(14)
Neutral -40.29
About Poly Medicure
Poly Medicure Limited is an Indian medical device manufacturer founded in 1995. The company produces over 130 SKUs of medical devices across various product verticals including infusion therapy, oncology, anesthesia, respiratory care, urology, gastroenterology, blood management, surgery, and dialysis. Poly Medicure operates ten manufacturing facilities across India, China, Egypt, and Italy, with seven in India, one in China through a wholly-owned subsidiary, one in Egypt through an associate, and one in Italy through a step-down subsidiary. The company exports to over 110 countries through a network of more than 220 distributors. Poly Medicure's facilities are accredited with international quality certifications, including ISO 9001:2015 and EN ISO 13485:2016. The company has an R&D center in Faridabad, Haryana, approved by DSIR, focusing on developing new products and improving existing processes. Poly Medicure holds over 375 patents for its products in various therapeutic areas.
Website
Chairperson NameDevendra Raj Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
